Literature DB >> 28871409

Retrospective analysis of treatments with recombinant FSH and recombinant LH versus human menopausal gonadotropin in women with reduced ovarian reserve.

Mario Mignini Renzini1, Claudio Brigante1, Giovanni Coticchio2, Mariabeatrice Dal Canto1, Ilaria Caliari1, Ruggero Comi1, Elena De Ponti3, Rubens Fadini1.   

Abstract

PURPOSES: The aim of this study is to determine whether a clinical advantage is gained with use of LH in combination with FSH or as a component of human menopausal gonadotropin (hMG) to achieve optimal ovarian stimulation.
METHODS: In this study, we compared retrospectively two regimens, r-FSH/r-LH and hMG, for the treatment of women with reduced ovarian reserve, identified as subjects with antral follicle count (AFC) < 11 and AMH ≤ 1.1 ng/ml.
RESULTS: Overall, the clinical pregnancy per started cycle was higher in the r-FSH/r-LH group (12.5 vs. 8.1%, P < 0.02), while implantation (11.1 vs. 9.5%) and miscarriage rates (29.9 vs. 35.9%) were comparable. Data were further analysed performing separate comparisons in subpopulations with different ranges of AFC, i.e. < 4, 4-6 and 7-10. Major differences between the two regimens were observed in women with AFC < 4. In this subpopulation, not only was the clinical pregnancies per started cycle higher in the r-FSH/r-LH group (10.2 vs. 1.5%, P < 0.01), but also implantation was significantly higher (13.0 vs. 2.8%, P < 0.02).
CONCLUSIONS: A r-FSH/r-LH regimen appears to be beneficial for the treatment of women with extremely poor ovarian reserve. It should be considered however that, being retrospective, this study is affected by obvious limitations, such as post-treatment patient selection criteria and absence of randomisation.

Entities:  

Keywords:  FSH; IVF; LH; Ovarian reserve; Ovarian stimulation; Poor responders; Pregnancy; hMG

Mesh:

Substances:

Year:  2017        PMID: 28871409      PMCID: PMC5714826          DOI: 10.1007/s10815-017-1034-z

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  21 in total

Review 1.  Gonadotropic control of ovarian follicular growth and development.

Authors:  S G Hillier
Journal:  Mol Cell Endocrinol       Date:  2001-06-20       Impact factor: 4.102

Review 2.  Ovarian antral folliculogenesis during the human menstrual cycle: a review.

Authors:  Angela R Baerwald; Gregg P Adams; Roger A Pierson
Journal:  Hum Reprod Update       Date:  2011-11-08       Impact factor: 15.610

3.  Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.

Authors:  T N L Vuong; H T Phung; M T Ho
Journal:  Hum Reprod       Date:  2015-03-03       Impact factor: 6.918

4.  Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles.

Authors:  Sesh Kamal Sunkara; Vivian Rittenberg; Nick Raine-Fenning; Siladitya Bhattacharya; Javier Zamora; Arri Coomarasamy
Journal:  Hum Reprod       Date:  2011-05-10       Impact factor: 6.918

Review 5.  Management of poor responders in IVF.

Authors:  F M Ubaldi; L Rienzi; S Ferrero; E Baroni; F Sapienza; L Cobellis; E Greco
Journal:  Reprod Biomed Online       Date:  2005-02       Impact factor: 3.828

Review 6.  Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis.

Authors:  Philippe Lehert; Joan C Schertz; Diego Ezcurra
Journal:  Reprod Biol Endocrinol       Date:  2010-09-16       Impact factor: 5.211

7.  Outcome from consecutive ICSI cycles in patients treated with recombinant human LH and those supplemented with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol.

Authors:  Francisco Fábregues; Montserrat Creus; Gemma Casals; Francisco Carmona; Juan Balasch
Journal:  Gynecol Endocrinol       Date:  2013-01-25       Impact factor: 2.260

Review 8.  GnRH agonist versus GnRH antagonist in ovarian stimulation: an ongoing debate.

Authors:  Raoul Orvieto; Pasquale Patrizio
Journal:  Reprod Biomed Online       Date:  2012-11-07       Impact factor: 3.828

9.  LH and hCG action on the same receptor results in quantitatively and qualitatively different intracellular signalling.

Authors:  Livio Casarini; Monica Lispi; Salvatore Longobardi; Fabiola Milosa; Antonio La Marca; Daniela Tagliasacchi; Elisa Pignatti; Manuela Simoni
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

10.  Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF: a systematic review and meta-analysis.

Authors:  Jin-song Xiao; Cun-mei Su; Xian-tao Zeng
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

View more
  6 in total

Review 1.  Management Strategies for POSEIDON Groups 3 and 4.

Authors:  Thor Haahr; Carlos Dosouto; Carlo Alviggi; Sandro C Esteves; Peter Humaidan
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-11       Impact factor: 5.555

Review 2.  Human Recombinant FSH and Its Biosimilars: Clinical Efficacy, Safety, and Cost-Effectiveness in Controlled Ovarian Stimulation for In Vitro Fertilization.

Authors:  Loredana Bergandi; Stefano Canosa; Andrea Roberto Carosso; Carlotta Paschero; Gianluca Gennarelli; Francesca Silvagno; Chiara Benedetto; Alberto Revelli
Journal:  Pharmaceuticals (Basel)       Date:  2020-06-27

3.  Ovarian Follicular Growth through Intermittent Vaginal Gonadotropin Administration in Diminished Ovarian Reserve Women.

Authors:  Chao-Chin Hsu; Isabel Hsu; Li-Hsuan Lee; Rosie Hsu; Yuan-Shuo Hsueh; Chih-Ying Lin; Hui Hua Chang
Journal:  Pharmaceutics       Date:  2022-04-15       Impact factor: 6.525

Review 4.  Luteinizing hormone supplementation in women with hypogonadotropic hypogonadism seeking fertility care: Insights from a narrative review.

Authors:  Noemi Di Segni; Andrea Busnelli; Matteo Secchi; Federico Cirillo; Paolo Emanuele Levi-Setti
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-01       Impact factor: 6.055

5.  A retrospective, matched case-control study of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.

Authors:  Ming-Jer Chen; Yu-Chiao Yi; Hwa-Fen Guu; Ya-Fang Chen; Hsiao-Fan Kung; Jui-Chun Chang; Shih-Ting Chuan; Li-Yu Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-15       Impact factor: 6.055

6.  A Randomized Controlled Trial on the Efficacy and Safety of Low-Dose hCG in a Short Protocol with GnRH Agonist and Ovarian Stimulation with Recombinant FSH (rFSH) During the Follicular Phase in Infertile Women Undergoing ART.

Authors:  Charalampos Siristatidis; Sofoklis Stavros; Konstantinos Dafopoulos; Theodoros Sergentanis; Ekaterini Domali; Peter Drakakis; Dimitrios Loutradis
Journal:  Reprod Sci       Date:  2021-07-12       Impact factor: 3.060

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.